International Journal of Cancer Management

Published by: Kowsar
Final Published scheduled for 9 (4)

Metastatic Anorectal Melanoma: A Case Report

R K Spartacus 1 , * , Rajan Paliwal 1 , Rohitashwa Dana 2 , Shwetha Mutha 1 , Prashant Bhatt 1 and Anees Malavat 1
Authors Information
1 Department of Radiotherapy, Jodhpur, Rajasthan University of Health Sciences, Rajasthan, India
2 Department of Radiotherapy, Sawai Man Singh (SMS) Medical College, Rajasthan University of Health Sciences, Rajasthan, India
Article information
  • Iranian Journal of Cancer Prevention: October 2016, 9 (5); e4756
  • Published Online: August 15, 2016
  • Article Type: Case Report
  • Received: November 20, 2015
  • Accepted: August 10, 2016
  • DOI: 10.17795/ijcp-4756

To Cite: Spartacus R K, Paliwal R, Dana R, Mutha S, Bhatt P, et al. Metastatic Anorectal Melanoma: A Case Report, Int J Cancer Manag. 2016 ; 9(5):e4756. doi: 10.17795/ijcp-4756.

Abstract
Copyright © 2016, Iranian Journal of Cancer Prevention. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
Acknowledgements
Footnotes
References
  • 1. Falch C, Stojadinovic A, Hann-von-Weyhern C, Protic M, Nissan A, Faries MB, et al. Anorectal malignant melanoma: extensive 45-year review and proposal for a novel staging classification. J Am Coll Surg. 2013; 217(2): 324-35[DOI][PubMed]
  • 2. Podnos YD, Tsai NC, Smith D, Ellenhorn JD. Factors affecting survival in patients with anal melanoma. Am Surg. 2006; 72(10): 917-20[PubMed]
  • 3. Goldman S, Glimelius B, Pahlman L. Anorectal malignant melanoma in Sweden. Report of 49 patients. Dis Colon Rectum. 1990; 33(10): 874-7[PubMed]
  • 4. Weinstock MA. Epidemiology and prognosis of anorectal melanoma. Gastroenterology. 1993; 104(1): 174-8[PubMed]
  • 5. Stoidis CN, Spyropoulos BG, Misiakos EP, Fountzilas CK, Paraskeva PP, Fotiadis CI. Diffuse anorectal melanoma; review of the current diagnostic and treatment aspects based on a case report. World J Surg Oncol. 2009; 7: 64[DOI][PubMed]
  • 6. Aytac B, Adim SB, Yerci O, Yilmazlar T. Anorectal malignant melanomas: experience of Uludag University. Kaohsiung J Med Sci. 2010; 26(12): 658-62[DOI][PubMed]
  • 7. Nam S, Kim CW, Baek SJ, Hur H, Min BS, Baik SH, et al. The clinical features and optimal treatment of anorectal malignant melanoma. Ann Surg Treat Res. 2014; 87(3): 113-7[DOI][PubMed]
  • 8. Kim KB, Sanguino AM, Hodges C, Papadopoulos NE, Eton O, Camacho LH, et al. Biochemotherapy in patients with metastatic anorectal mucosal melanoma. Cancer. 2004; 100(7): 1478-83[DOI][PubMed]
  • 9. Yeh JJ, Shia J, Hwu WJ, Busam KJ, Paty PB, Guillem JG, et al. The role of abdominoperineal resection as surgical therapy for anorectal melanoma. Ann Surg. 2006; 244(6): 1012-7[DOI][PubMed]
  • 10. Yeh JJ, Weiser MR, Shia J, Hwu WJ. Response of stage IV anal mucosal melanoma to chemotherapy. Lancet Oncol. 2005; 6(6): 438-9[DOI][PubMed]
  • 11. Serrone L, Zeuli M, Sega FM, Cognetti F. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview. J Exp Clin Cancer Res. 2000; 19(1): 21-34[PubMed]
  • 12. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364(26): 2517-26[DOI][PubMed]
  • 13. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26): 2507-16[DOI][PubMed]
  • 14. Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012; 380(9839): 358-65[DOI][PubMed]
  • 15. Hodi FS, Friedlander P, Corless CL, Heinrich MC, Mac Rae S, Kruse A, et al. Major response to imatinib mesylate in KIT-mutated melanoma. J Clin Oncol. 2008; 26(12): 2046-51[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments